Despite positive clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable difficulty from managed care entities. Such insurers are typically erecting obstacles to access, including significant expense restrictions and prior authorization that limit patient availabil